The landscape of breast cancer treatment continues to evolve. Targeted therapies are transforming HR+ early-stage and metastatic breast cancer treatment as well as HER2+ metastatic breast cancer, but they require careful consideration of dosing variations, administration schedules, and potential adverse effects (AEs). PTCE’s 2025 Breast Cancer Day of Education will provide oncology pharmacists with practical, evidence-based updates on the use of targeted therapies across early-stage and metastatic breast cancer. Sessions will focus on the evolving role of CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, oral SERDs, and HER2-targeted therapies in both HR+/HER2− and HER2+ disease. Faculty will review current treatment guidelines, key clinical trial data, and considerations for sequencing therapies based on molecular markers and resistance mechanisms. Case-based discussions will highlight strategies for managing AEs, adjusting doses, and supporting patient adherence. Additional sessions will address the pharmacist’s role in identifying high-risk disease, interpreting mutational testing, and counseling patients on treatment expectations and self-management. Video vignettes and expert panels will provide real-world perspectives on communication, education, and clinical decision-making in breast cancer care.

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Each CE broadcast/symposium is approved for application-based credit.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.